The quality of medicinal products is imperative to support their safety and efficacy. A.P.P.A.® Project proposes as primary objective the realization of galenic labs with the aim to prepare galenics which show the above requisite, looking at the compliance of patients living in Developing Countries (DC). The circulation of substandard medicines in the DC is a serious clinical and public health concern. Counterfeiting includes under or over concentration of pharmaceutical ingredients, contamination, poor quality ingredients, poor stability and inadequate packaging. The quality of more than 200 samples, sold in the Countries in which A.P.P.A.® labs are working, has been studied. Results showed that a substantial percentage of samples is substandard (52%) and thus have to be considered as a counterfeit. Into account the results obtained, a specific study was carried on some medicines purchased from two of the largest wholesalers operating in Cameroun: between March 2011 and May 2012 54 industrial medicinal product were analyzed. The 72% (39) of samples were found to be counterfeit, 37 imperfect and 2 criminal counterfeits. The 2 criminal counterfeits were sold by the same wholesaler. The data collected stimulate to increase the activity of A.P.P.A.® in Cameroun

A.P.P.A.® Project (Aid Progress Pharmacist Agreement) against the phenomenon of counterfeit medicines

BARATTA, Francesca;GERMANO, ANTONIO;BRUSA, Paola
2012

Abstract

The quality of medicinal products is imperative to support their safety and efficacy. A.P.P.A.® Project proposes as primary objective the realization of galenic labs with the aim to prepare galenics which show the above requisite, looking at the compliance of patients living in Developing Countries (DC). The circulation of substandard medicines in the DC is a serious clinical and public health concern. Counterfeiting includes under or over concentration of pharmaceutical ingredients, contamination, poor quality ingredients, poor stability and inadequate packaging. The quality of more than 200 samples, sold in the Countries in which A.P.P.A.® labs are working, has been studied. Results showed that a substantial percentage of samples is substandard (52%) and thus have to be considered as a counterfeit. Into account the results obtained, a specific study was carried on some medicines purchased from two of the largest wholesalers operating in Cameroun: between March 2011 and May 2012 54 industrial medicinal product were analyzed. The 72% (39) of samples were found to be counterfeit, 37 imperfect and 2 criminal counterfeits. The 2 criminal counterfeits were sold by the same wholesaler. The data collected stimulate to increase the activity of A.P.P.A.® in Cameroun
Convegno ADRITELF
Firenze
13-16 settembre 2012
40 anni di Tecnologia Farmaceutica
52
52
F. Baratta; A. Germano; P. Brusa
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/151788
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact